Andrew Combs
2020
In 2020, Andrew Combs earned a total compensation of $2M as EVP and Head of Chemistry at Prelude Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $160,988 |
|---|---|
| Option Awards | $1,533,537 |
| Salary | $321,538 |
| Total | $2,016,063 |
Combs received $1.5M in option awards, accounting for 76% of the total pay in 2020.
Combs also received $161K in non-equity incentive plan and $321.5K in salary.
Rankings
In 2020, Andrew Combs' compensation ranked 5,466th out of 13,090 executives tracked by ExecPay. In other words, Combs earned more than 58.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,466 out of 13,090 | 58th |
Division Manufacturing | 2,247 out of 5,624 | 60th |
Major group Chemicals And Allied Products | 894 out of 2,257 | 60th |
Industry group Drugs | 771 out of 1,957 | 61st |
Industry Pharmaceutical Preparations | 576 out of 1,462 | 61st |
Source: SEC filing on April 29, 2022.
Combs' colleagues
We found three more compensation records of executives who worked with Andrew Combs at Prelude Therapeutics in 2020.